^131I标记抗VEGFR2靶向性纳米载体对未分化甲状腺癌的抑瘤作用  

Targeted Molecular Diagnosis and Therapy Antitumor effect of ^131I-labeled anti-VEGFR2 targeted nanoparticles in anaplastic thyroid carcinoma mouse models

作　　者：王任飞[1] 张瑞国[1] 张月倩 谌红彬 李宁[1] 张富海[1] 王汉杰 常津 张桂芝[1] 谭建[1] Wang Renfei;Zhang Ruiguo;Zhang Yueqian;Chen Hongbin;Li Ning;Zhang Fuhai;Wang Hanjie;Chang Jin;Zhang Guizhi;Tan Jian(Department of Nuclear Medicine,Tianjin Medical University General Hospital,Tianjin 300052,Chin;School of Life Sciences,Tianjin University,Tianjin 300072,China)

机构地区：[1]天津医科大学总医院核医学科,300052 [2]天津大学生命科学学院,300072

出　　处：《中华核医学与分子影像杂志》2018年第11期716-720,共5页Chinese Journal of Nuclear Medicine and Molecular Imaging

摘　　要：目的观察131I－牛血清白蛋白（BSA）－介孔二氧化硅纳米粒（MSNs）－抗血管内皮生长因子受体2（anti－VEGFR2）在未分化甲状腺癌（ATC）荷瘤裸鼠体内的靶向性分布及其抑瘤作用。方法构建131I－BSA－MSNs－anti－VEGFR2与131I－BSA－MSNs。分别于人ATC细胞FRO荷瘤裸鼠瘤体内注射131I－BSA－MSNs－anti－VEGFR2（靶向组）、131I－BSA－MSNs（非靶向组）、Na131I（Na131I组）和生理盐水（对照组），通过SPECT/CT显像观察注射后不同时间荷瘤裸鼠体内的放射性分布，记录各组荷瘤裸鼠的体质量及肿瘤体积变化。采用两样本t检验和log－rank法分析数据。结果温育3 h后，靶向组细胞荧光强度（345.26±16.35）高于非靶向组（280.61±9.65；t＝5.90，P〈0.05）。SPECT/CT显像示，注射后1～3周，靶向组肿瘤内放射性分布明显强于非靶向组（t值：7.060～12.780，均P〈0.05）。观察结束时，Na131I组、对照组、非靶向组、靶向组的肿瘤体积分别增大至原来的（278.3±19.3）%、（296.6±24.2）%、（198.7±13.2）%和（103.7±6.2）%；前2组裸鼠体质量分别减少为原来的（88.6±3.0）%和（86.2±3.1）%，而后2组则增加至原来的（102.1±3.1）%和（116.2±3.4）%。生存分析曲线显示，靶向组的生存期（38 d）明显高于非靶向组（34 d; χ2＝8.05，P〈0.05）。结论131I－BSA－MSNs－anti－VEGFR2可有效抑制ATC的肿瘤生长，延长荷瘤裸鼠生存期，在ATC的治疗和预后评估中有良好的应用前景。ObjectiveTo investigate the radioactivity distribution of 131I-bovine serum albumin （BSA）-mesoporous silica nanoparticles （MSNs）-anti-vascular endothelial growth factor receptor 2 （VEGFR2） in anaplastic thyroid carcinoma （ATC） and to explore its antitumor efficacy in ATC-bearing nude mouse models.Methods131I-BSA-MSNs-anti-VEGFR2 and 131I-BSA-MSNs were constructed. FRO tumor xenografts were established and the SPECT/CT images of tumor-bearing mice were acquired at different time points after intratumoral injection with 131I-BSA-MSNs-anti-VEGFR2 （targeting group）, 131I-BSA-MSNs （non-targeting group）, Na131I （Na131I group） and saline （control group）, respectively. The changes of body mass and tumor volume in each group were recorded. Two-sample t test and log-rank test were used to analyze the data.ResultsAfter incubation for 3 h, the fluorescence intensity in targeting group was higher than that in non-targeting group （345.26±16.35 vs 280.61±9.65; t=5.90, P〈0.05）. After injection for 1-3 weeks, the radioactivity detected by SPECT/CT in targeting group was obviously stronger than that in non-targeting group （t values： 7.060-12.780, all P〈0.05）. At the end of the observation, the tumor volume of Na131I group, control group, non-targeting group and targeting group increased to （278.3±19.3）%, （296.6±24.2）%, （198.7±13.2）% and （103.7±6.2）% of the original volume, respectively. The body mass of the first 2 groups decreased to （88.6±3.0）% and （86.2±3.1）% of the original body mass respectively, while that of the latter 2 groups increased to （102.1±3.1）% and （116.2±3.4）% of the original body mass respectively. Survival analysis showed that the median survival time in targeting group （38 d） was significantly longer than that in non-targeting group （34 d; χ2=8.05, P〈0.05）.Conclusion131I-BSA-MSNs-anti-VEGFR2 can effectively inhibit the tumor growth of ATC and prolong the survival of tumor-bearing nude mice, which gives a good sugg

关 键 词：甲状腺肿瘤 血管内皮生长因子受体2 纳米粒 碘放射性同位素 体层摄影术 发射型计算机  单光子 体层摄影术 X线计算机 小鼠  裸 

分 类 号：R736.1[医药卫生—肿瘤]